BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmuCell (ICCC) Announces Product Sales Increases and Other Financial Results


2/14/2013 9:06:20 AM

PORTLAND, ME--(Marketwire - February 14, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2012.

"Despite the ongoing economic hardships faced by our customers, we ended the year with strong product sales in the fourth quarter. Sales of our lead product, First Defense®, increased by 16% and 5% during the fourth quarter and for the full year, respectively, over 2011 levels," commented Michael F. Brigham, President and CEO. "As projected, our bottom line performance improved from a loss in 2011 to a profit in 2012."

During the three-month period ended December 31, 2012, product sales increased by 9%, or $116,000, to $1,421,000 in comparison to the same period in 2011. During the year ended December 31, 2012, product sales increased by 5.5%, or $279,000, to $5,390,000 in comparison to 2011.

The net operating income was $245,000 during the year ended December 31, 2012, in contrast to a net operating loss of ($633,000) during 2011. The net income was $90,000, or $0.03 per share, during the year ended December 31, 2012, in contrast to a net loss of ($410,000), or ($0.14) per share, for 2011. The improved financial performance is principally due to planned reductions in product development expenses associated with the Mast Out® product development initiative, as well as increased gross margin from sales of First Defense®. The Company remains actively engaged in pursuing the necessary financing to complete the Mast Out® initiative.

Cash, cash equivalents and short-term investments decreased by less than 1%, or $46,000, to $4,914,000 at December 31, 2012 as compared to $4,960,000 at December 31, 2011. Stockholders' equity increased by 2%, or $174,000, to $9,195,000 at December 31, 2012 as compared to $9,020,000 at December 31, 2011. The Company had 3,019,000 shares of common stock outstanding as of December 31, 2012.

                                                                            
                                      (Unaudited)                           
                                  For the Three-Month  For the Twelve-Month 
                                     Periods Ended         Periods Ended    
                                     December 31,          December 31,     
                                 --------------------  -------------------- 
(In thousands, except per share                                             
 amounts)                           2012       2011       2012       2011   
                                 ---------  ---------  ---------- --------- 
                                                                            
Product sales                    $   1,421  $   1,305  $    5,390 $   5,111 
Costs of goods sold                    671        580       2,336     2,297 
                                 ---------  ---------  ---------- --------- 
    Gross margin                       750        725       3,054     2,814 
                                                                            
Product development expenses           234        271         918     1,720 
Selling and administrative                                                  
 expenses                              503        445       1,891     1,727 
                                 ---------  ---------  ---------- --------- 
    Other operating expenses           737        716       2,809     3,447 
                                 ---------  ---------  ---------- --------- 
                                                                            
NET OPERATING INCOME (LOSS)             13          9         245      (633)
                                                                            
Other expenses, net                     24          7          53        64 
                                 ---------  ---------  ---------- --------- 
                                                                            
(LOSS) INCOME BEFORE INCOME                                                 
 TAXES                                 (11)         2         192      (697)
                                                                            
Income tax expense (benefit)             6          3         102      (287)
                                 ---------  ---------  ---------- --------- 
                                                                            
NET (LOSS) INCOME                $     (17) $      (1) $       90 $    (410)
                                 =========  =========  ========== ========= 
                                                                            
Weighted average common shares                                              
 outstanding:                                                               
  Basic                              3,019      3,001       3,018     2,985 
  Diluted                            3,019      3,001       3,108     2,985 
                                                                            
NET (LOSS) INCOME PER SHARE:                                                
  Basic                          $   (0.01) $   (0.00) $     0.03 $   (0.14)
  Diluted                        $   (0.01) $   (0.00) $     0.03 $   (0.14)
                                                                            
                                                                            
                                                                            
                                                   As of           As of    
                                                December 31,    December 31,
(In thousands)                                      2012           2011     
                                               -------------- --------------
                                                                            
Cash, cash equivalents and short-term                                       
 investments                                   $        4,914 $        4,960
Total assets                                           11,030         10,991
Net working capital                                     6,697          6,516
Stockholders' equity                           $        9,195 $        9,020
                                                                            

About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).


Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES